

COFFEE & CODING

Monday, December 11, 2023

More HCPCS coding changes you need to know now...

In last week's Coffee & Coding, we addressed some of the roughly 350 additions to HCPCS codes that go into effect on January 1. This week, we'll highlight the rest of the changes you'll need to prepare for. Grab a fresh cup of joe and let's dive in!

J0184	ADD	Inj, amisulpride, 1 mg	Injection, amisulpride, 1 mg
J0217	ADD	Inj velmanase alfa-tycv 1 mg	Injection, velmanase alfa-tycv, 1 mg
J0391	ADD	Inj, artesunate, 1mg	Injection, artesunate, 1 mg
J0402	ADD	Inj, abilify asimtufii, 1 mg	Injection, aripiprazole (abilify asimtufii), 1 mg
J0576	ADD	Inj buprenorph (brixadi) 1mg	Injection, buprenorphine extended-release (brixadi), 1 mg
J0688	ADD	Inj cefazolin sodium, hikma	Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg
J0750	ADD	Hiv prep, ftc/tdf 200/300mg	Emtricitabine 200mg and tenofovir disoproxil fumarate 300mg, oral, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv)
J0751	ADD	Hiv prep, ftc/taf 200/25mg	Emtricitabine 200mg and tenofovir alafenamide 25mg, oral, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv)
J0799	ADD	Hiv prep, fda approved, noc	Fda approved prescription drug, only for use as hiv pre-exposure prophylaxis (not for use as treatment of hiv), not otherwise classified
J0873	ADD	Inj, daptomycin (xellia)	Injection, daptomycin (xellia) not therapeutically equivalent to j0878, 1 mg
J1105	ADD	Dexmedetomidine film, 1 mcg	Dexmedetomidine, oral, 1 mcg
J1246	ADD	Inj, dinutuximab, 0.1 mg	Injection, dinutuximab, 0.1 mg
J1304	ADD	Inj tofersen intrathec 1 mg	Injection, tofersen, 1 mg
J1412	ADD	Inj roctavian ml 2x10 ¹³ vc g	Injection, valoctocogene roxaparovec-rox, per ml, containing nominal 2 x 10 ¹³ vector genomes
J1413	ADD	Inj delandistrogene mox rokl	Injection, delandistrogene moxeparovec-rokl, per therapeutic dose
J1596	ADD	Inj, glycopyrrolate, 0.1 mg	Injection, glycopyrrolate, 0.1 mg
J1939	ADD	Inj, bumetanide, 0.5 mg	Injection, bumetanide, 0.5 mg
J2404	ADD	Inj, nicardipine 0.1 mg	Injection, nicardipine, 0.1 mg
J2508	ADD	Pegunigalsidase alfa-iwxj	Injection, pegunigalsidase alfa-iwxj, 1 mg
J2679	ADD	Inj fluphenazine hcl 1.25 mg	Injection, fluphenazine hcl, 1.25 mg
J2799	ADD	Inj, uzedy, 1 mg	Injection, risperidone (uzedy), 1 mg
J3401	ADD	Vyjuvek 5x10 ⁹ pfu/ml, 0.1 ml	Beremagene geperpavec-svdt for topical administration, containing nominal 5 x 10 ⁹ pfu/ml vector genomes, per 0.1 ml
J3425	ADD	Inj, hydroxocobalamin	Injection, hydroxocobalamin, 10 mcg
J9052	ADD	Inj, carmustine (accord)	Injection, carmustine (accord), not therapeutically equivalent to j9050, 100 mg
J9072	ADD	Inj cyclophos dr.reddy's 5mg	Injection, cyclophosphamide, (dr. reddy's), 5 mg
J9172	ADD	Docetaxel (ingenus), 1 mg	Injection, docetaxel (ingenus) not therapeutically equivalent to j9171, 1 mg
J9255	ADD	Inj, methotrexate (accord)	Injection, methotrexate (accord) not therapeutically equivalent to j9250 and j9260, 50 mg
J9258	ADD	Paclitaxel (teva)	Injection, paclitaxel protein-bound particles (teva) not therapeutically equivalent to j9264, 1 mg
J9286	ADD	Inj glofitamab gxbm, 2.5 mg	Injection, glofitamab-gxbm, 2.5 mg
J9321	ADD	Inj epcoritamab-bysp 0.16 mg	Injection, epcoritamab-bysp, 0.16 mg
J9324	ADD	Inj, pemrydi rtu, 10 mg	Injection, pemetrexed (pemrydi rtu), 10 mg
J9333	ADD	Inj ronzanolixizum-noli 1 mg	Injection, ronzanolixizumab-noli, 1 mg
J9334	ADD	Inj efqart-alfa 2mq hya-qvfc	Injection, efqartigimod alfa, 2 mg and hyaluronidase-qvfc



L3161	ADD	Foot, adductus position, adj	Foot, adductus positioning device, adjustable
L5615	ADD	Ak 4 bar link hydrl swg/stanc	Addition, endoskeletal knee-shin system, 4 bar linkage or multiaxial, fluid swing and stance phase control
M5926	ADD	Endoskel posit rotat unit	Addition to lower extremity prosthesis, endoskeletal, knee disarticulation, above knee, hip disarticulation, positional rotation unit, any type
M1219	ADD	Anphx due to vax	Anaphylaxis due to the vaccine on or before the date of the encounter
M1220	ADD	Dre wth interp rtnophy	Dilated retinal eye exam with interpretation by an ophthalmologist or optometrist or artificial intelligence (ai) interpretation documented and reviewed; with evidence of retinopathy
M1221	ADD	Dre w/o rtnophy	Dilated retinal eye exam with interpretation by an ophthalmologist or optometrist or artificial intelligence (ai) interpretation documented and reviewed; without evidence of retinopathy
M1222	ADD	Glaucoma pln of care not doc	Glaucoma plan of care not documented, reason not otherwise specified
M1223	ADD	Glaucoma plan of care doc	Glaucoma plan of care documented
M1224	ADD	Iop dec <20% from base	Intraocular pressure (iop) reduced by a value less than 20% from the pre-intervention level
M1225	ADD	Iop dec >=20% from base	Intraocular pressure (iop) reduced by a value of greater than or equal to 20% from the pre-intervention level
M1226	ADD	Iop not doc	Iop measurement not documented, reason not otherwise specified
M1227	ADD	Eb therapy prescribed	Evidence-based therapy was prescribed
M1228	ADD	Pt + hcv aby +vir w/ rx 3 mo	Patient, who has a reactive hcv antibody test, and has a follow up hcv viral test that detected hcv viremia, has hcv treatment initiated within 3 months of the reactive hcv antibody test
M1229	ADD	Pt w/ +hcv +vir ref win 1 mo	Patient, who has a reactive hcv antibody test, and has a follow up hcv viral test that detected hcv viremia, is referred within 1 month of the reactive hcv antibody test to a clinician who treats hcv infection
M1230	ADD	Pt hcv rctv aby no f/u tst	Patient has a reactive hcv antibody test and does not have a follow up hcv viral test, or patient has a reactive hcv antibody test and has a follow up hcv viral test that detects hcv viremia and is not referred to a clinician who treats hcv infection within 1 month and does not have hcv treatment initiated within 3 months of the reactive hcv antibody test, reason not given
M1231	ADD	Pt hcv tst no reactive res	Patient receives hcv antibody test with nonreactive result
M1232	ADD	Pt hcv tst reactive result	Patient receives hcv antibody test with reactive result
M1233	ADD	Pt no hcv aby or result	Patient does not receive hcv antibody test or patient does receive hcv antibody test but results not documented, reason not given
M1234	ADD	Pt hcv rctv aby f/u neg	Patient has a reactive hcv antibody test, and has a follow up hcv viral test that does not detect hcv viremia
M1235	ADD	Doc of hcv abv rna tst	Documentation or patient report of hcv antibody test or hcv rna test which occurred prior to the performance period
M1255	ADD	Pts w/ othr rsn vst,+prg tst	Patients who were not listed on the kidney-pancreas transplant waitlist or patients who did not receive a living donor transplant within the first year following initiation of dialysis
M1256	ADD	Prior history of known cvd	Prior history of known cvd
M1257	ADD	Cvd risk assess not perf	Cvd risk assessment not performed or incomplete (e.g., cvd risk assessment was not documented), reason not otherwise specified
M1258	ADD	Cvd risk assess perf	Cvd risk assessment performed, have a documented calculated risk score
M1259	ADD	Pt kid transplt wtlst lv don	Patients listed on the kidney-pancreas transplant waitlist or who received a living donor transplant within the first year following initiation of dialysis
M1260	ADD	Pt no kd trnsplt wtlst lv do	Patients who were not listed on the kidney-pancreas transplant waitlist or patients who did not receive a living donor transplant within the first year following initiation of dialysis
M1261	ADD	Pts on wtlist bef dialysis	Patients that were on the kidney or kidney-pancreas waitlist prior to initiation of dialysis
M1262	ADD	Pts transplt bef dialysis	Patients who had a transplant prior to initiation of dialysis
M1263	ADD	Pts hosp dialysis dt	Patients in hospice on their initiation of dialysis date or during the month of evaluation
M1264	ADD	Pts 75+ dialysis dt	Patients age 75 or older on their initiation of dialysis date
M1265	ADD	Cms 2728 completed	Cms medical evidence form 2728 for dialysis patients: initial form completed
M1266	ADD	Pts admit snf	Patients admitted to a skilled nursing facility (snf)



M1267	ADD	Pt no act kid transpl wtst	Patients not on any kidney or kidney-pancreas transplant waitlist or is not in active status on any kidney or kidney-pancreas transplant waitlist as of the last day of each month during the measurement period
M1268	ADD	Pt ac stat kid transpl wtst	Patients on active status on any kidney or kidney-pancreas transplant waitlist as of the last day of each month during the measurement period
M1269	ADD	Rec'd esrd mcp 1st day of mo	Receiving esrd mcp dialysis services by the provider on the last day of the reporting month
M1270	ADD	Pts no kid transpl wtst	Patients not on any kidney or kidney-pancreas transplant waitlist as of the last day of each month during the measurement period
M1299	ADD	Flu immunize order/admin	Influenza immunization administered or previously received
M1300	ADD	Flu imm no admin doc rea	Influenza immunization was not administered for reasons documented by clinician (e.g., patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons)
M1301	ADD	Pt recv tbco cess interv	Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy)
M1302	ADD	Scrn mam perf rsults doc	Screening, diagnostic, film digital or digital breast tomosynthesis (3d) mammography results documented and reviewed
M1303	ADD	Hospic serv dur meas pd	Hospice services provided to patient any time during the measurement period
M1304	ADD	No pneum vax admin 19+	Patient did not receive any pneumococcal conjugate or polysaccharide vaccine on or after their 19th birthday and before the end of the measurement period
M1305	ADD	Pneum vax admin 19+	Patient received any pneumococcal conjugate or polysaccharide vaccine on or after their 19th birthday and before the end of the measurement period
M1306	ADD	Pt anphx due to pneum	Patient had anaphylaxis due to the pneumococcal vaccine any time during or before the measurement period
M1307	ADD	Doc pt pal or hospice	Documentation stating the patient has received or is currently receiving palliative or hospice care
M1308	ADD	Flu immunize no admin	Influenza immunization was not administered, reason not given
Q0516	ADD	Supply fee hiv prep 30-days	Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription drug, per 30-days
Q0517	ADD	Supply fee hiv prep 60-days	Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription drug, per 60-days
Q0518	ADD	Supply fee hiv prep 90-days	Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription drug, per 90-days
Q4279	ADD	Vendaje ac, per sq cm	Vendaje ac, per square centimeter
Q4287	ADD	Dermabind dl, per sq cm	Dermabind dl, per square centimeter
Q4288	ADD	Dermabind ch, per sq cm	Dermabind ch, per square centimeter
Q4289	ADD	Revoshield+ amnio, per sq cm	Revoshield + amniotic barrier, per square centimeter
Q4290	ADD	Membrane wrap hydr per sq cm	Membrane wrap-hydro, per square centimeter
Q4291	ADD	Lamellas xt, per sq cm	Lamellas xt, per square centimeter
Q4292	ADD	Lamellas, per sq cm	Lamellas, per square centimeter
Q4293	ADD	Acesso dl, per sq cm	Acesso dl, per square centimeter
Q4294	ADD	Amnio quad-core, per sq cm	Amnio quad-core, per square centimeter
Q4295	ADD	Amnio tri-core, per sq cm	Amnio tri-core amniotic, per square centimeter
Q4296	ADD	Rebound matrix, per sq cm	Rebound matrix, per square centimeter
Q4297	ADD	Emerge matrix, per sq cm	Emerge matrix, per square centimeter
Q4298	ADD	Amnicore pro, per sq cm	Amnicore pro, per square centimeter
Q4299	ADD	Amnicore pro+, per sq cm	Amnicore pro+, per square centimeter
Q4300	ADD	Acesso tl, per sq cm	Acesso tl, per square centimeter
Q4301	ADD	Activate matrix, per sq cm	Activate matrix, per square centimeter
Q4302	ADD	Complete aca, per sq cm	Complete aca, per square centimeter
Q4303	ADD	Complete aa, per sq cm	Complete aa, per square centimeter
Q4304	ADD	Grafix plus, per sq cm	Grafix plus, per square centimeter
Q5132	ADD	Inj, abrilada, 10 mg	Injection, adalimumab-afzb (abrilada), biosimilar, 10 mg

For a complete list of coding changes, see:
[HCPCS Quarterly Update | CMS](#)



**Got a question about E/M coding? We'd love to hear from you.
Submit your questions by emailing us at coders@calmwatersai.com!**



Michelle Sergei-Casiano

CPC, CFPC, CEMC

Senior Manager, Regulatory and Coding Compliance